| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Departments of Obstetrics and Gynecology; Division of Gynecologic Oncology [M. K. D., W. A. C., K. C. P.], Oncology [L. C. H.], Laboratory Medicine and Pathology [K. A. D., G. L. K., S. R. R., R. B. J.], Biostatistics [J. Q. S.], and Medical Genetics [R. B. J.], Mayo Clinic and Foundation, Rochester, Minnesota 55905
1 To whom requests for reprints should be addressed, at Cytogenetics Laboratory, Mayo Clinic, 200 First Street S.W., Rochester, MN 55905.
Loss of heterozygosity (LOH) studies were performed to investigate the genetic differences which separate low-grade (LG), high-grade (HG), and borderline epithelial ovarian carcinomas.
Fresh tumor samples and blood were obtained from 58 patients (20 LG, 34 HG, and 4 borderline tumor specimens) undergoing surgery for ovarian carcinoma at Mayo Clinic. Tumors were graded using a modified Broder's classification with invasive grades 1 and 2 considered LG, invasive grades 3 and 4 considered HG, and tumors with no evidence of stromal invasion classified as borderline. Polymorphism analysis was performed using 76 restriction fragment length polymorphisms and variable number of tandem repeats and 59 microsatellite markers representing all chromosome arms.
Chromosome arms 6p, 17p, 17q, and 22q were found to be frequently lost in LG as well as HG tumors. Chromosome arms 13q and 15q were lost to a significantly greater extent in HG tumors compared to LG neoplasms (P = 0.003 and P = 0.08, respectively). Conversely, 3p loss was seen more frequently with LG tumors (P = 0.02). The majority of LG tumors (65%) did not show frequent LOH in the allelotype analysis. In fact, a subset of 7 (7 of 20) LG tumors accounted for 76% of the total allelic loss in the LG category. These tumors showed LOH almost identical to that of the HG neoplasms. Borderline tumors showed a low rate of allelic loss. There were no common events found between borderline and invasive tumors.
Our data suggest that most HG tumors and a subset of LG tumors share genetic alterations at putative tumor suppressor genes detected by LOH studies. Chromosome 6 and 17 losses appear to be early events while 13q and 15q losses appear to be critical late events. However, a majority of LG tumors appear to develop as a consequence of an alternative mechanism(s) which is not detected by LOH studies. Possibilities include: (a) inactivation of tumor suppressor genes without LOH; (b) dominant negative gene(s) in which only one allele requires mutation; and (c) changes in dominant acting oncogenes. This unidentified phenomenon may be operative in borderline tumors as well.
The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
Received 7/ 9/93. Accepted 8/19/93.
This article has been cited by other articles:
|
|
 |
|
  C. N. Landen Jr, M. J. Birrer, and A. K. Sood Early Events in the Pathogenesis of Epithelial Ovarian Cancer J. Clin. Oncol., February 20, 2008; 26(6): 995 - 1005. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. A. Bergamo, L. C. da Silva Veiga, P. P. dos Reis, I. N. Nishimoto, J. Magrin, L. P. Kowalski, J. A. Squire, and S. R. Rogatto Classic and Molecular Cytogenetic Analyses Reveal Chromosomal Gains and Losses Correlated with Survival in Head and Neck Cancer Patients Clin. Cancer Res., January 15, 2005; 11(2): 621 - 631. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Natrajan, J. Louhelainen, S. Williams, J. Laye, and M. A. Knowles High-Resolution Deletion Mapping of 15q13.2-q21.1 in Transitional Cell Carcinoma of the Bladder Cancer Res., November 15, 2003; 63(22): 7657 - 7662. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H.-W. Chang, S. M. Lee, S. N. Goodman, G. Singer, S. K. R. Cho, L. J. Sokoll, F. J. Montz, R. Roden, Z. Zhang, D. W. Chan, et al. Assessment of Plasma DNA Levels, Allelic Imbalance, and CA 125 as Diagnostic Tests for Cancer J Natl Cancer Inst, November 20, 2002; 94(22): 1697 - 1703. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A P M Jongsma, J M J Piek, R P Zweemer, R H M Verheijen, J W T Klein Gebbinck, G J van Kamp, I J Jacobs, P Shaw, P J van Diest, and P Kenemans Molecular evidence for putative tumour suppressor genes on chromosome 13q specific to BRCA1 related ovarian and fallopian tube cancer Mol. Pathol., October 1, 2002; 55(5): 305 - 309. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H.-W. Chang, S. Z. Ali, S. K. R. Cho, R. J. Kurman, and I.-M. Shih Detection of Allelic Imbalance in Ascitic Supernatant by Digital Single Nucleotide Polymorphism Analysis Clin. Cancer Res., August 1, 2002; 8(8): 2580 - 2585. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Singer, R. J. Kurman, H.-W. Chang, S. K.R. Cho, and I.-M. Shih Diverse Tumorigenic Pathways in Ovarian Serous Carcinoma Am. J. Pathol., April 1, 2002; 160(4): 1223 - 1228. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. N. Manderson, A.-M. Mes-Masson, J. Novak, P. D. Lee, D. Provencher, T. J. Hudson, and P. N. Tonin Expression Profiles of 290 ESTs Mapped to Chromosome 3 in Human Epithelial Ovarian Cancer Cell Lines Using DNA Expression Oligonucleotide Microarrays Genome Res., January 1, 2002; 12(1): 112 - 121. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. G. Tibiletti, B. Bernasconi, D. Furlan, P. Bressan, R. Cerutti, C. Facco, M. Franchi, C. Riva, R. Cinquetti, C. Capella, et al. Chromosome 6 Abnormalities in Ovarian Surface Epithelial Tumors of Borderline Malignancy Suggest a Genetic Continuum in the Progression Model of Ovarian Neoplasms Clin. Cancer Res., November 1, 2001; 7(11): 3404 - 3409. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
V. W. Wang, D. A. Bell, R. S. Berkowitz, and S. C. Mok Whole Genome Amplification and High-Throughput Allelotyping Identified Five Distinct Deletion Regions on Chromosomes 5 and 6 in Microdissected Early-Stage Ovarian Tumors Cancer Res., May 1, 2001; 61(10): 4169 - 4174. [Abstract] [Full Text]
|
|
|
|
|
|
S. Suzuki, D. H. Moore II, D. G. Ginzinger, T. E. Godfrey, J. Barclay, B. Powell, D. Pinkel, C. Zaloudek, K. Lu, G. Mills, et al. An Approach to Analysis of Large-Scale Correlations between Genome Changes and Clinical Endpoints in Ovarian Cancer Cancer Res., October 1, 2000; 60(19): 5382 - 5385. [Abstract] [Full Text]
|
|
|
|
|
|
P. Fullwood, S. Marchini, J. S. Rader, A. Martinez, D. Macartney, M. Broggini, C. Morelli, G. Barbanti-Brodano, E. R. Maher, and F. Latif Detailed Genetic and Physical Mapping of Tumor Suppressor Loci on Chromosome 3p in Ovarian Cancer Cancer Res., September 1, 1999; 59(18): 4662 - 4667. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Kudoh, M. Takano, T. Koshikawa, M. Hirai, S. Yoshida, Y. Mano, K. Yamamoto, K. Ishii, T. Kita, Y. Kikuchi, et al. Gains of 1q21-q22 and 13q12-q14 Are Potential Indicators for Resistance to Cisplatin-based Chemotherapy in Ovarian Cancer Patients Clin. Cancer Res., September 1, 1999; 5(9): 2526 - 2531. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. S. Bates, W. E. Farrell, E. J. Bicknell, A. M. McNicol, A. J. Talbot, J. C. Broome, C. W. Perrett, R. V. Thakker, and R. N. Clayton Allelic Deletion in Pituitary Adenomas Reflects Aggressive Biological Activity and Has Potential Value as a Prognostic Marker J. Clin. Endocrinol. Metab., March 1, 1997; 82(3): 818 - 824. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |
